ArticleAntibody therapeutics2024

Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity.

Yang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.